Loading
QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.
QLH12016 is a protein degrader developed by Qilu Pharmaceutical. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07198633, plans to enrol 212 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Protein degrader directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Androgen receptor.
1.QLH12016 binds Androgen receptor with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"QLH12016" OR ABSTRACT:"QLH12016") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QLH12016, not a curated reading list.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer, Qilu Pharmaceutical, Prostate cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.